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Résumé 
Il est connu depuis longtemps que le zinc (Zn) est primordial pour la croissance et 
maintien des systèmes biologiques. De plus, le Zn a aussi démontré des propriétés 
insulino-mimetiques et anti-diabétiques, comparables à l'insuline dans des cellules isolées, 
des tissus, ainsi que chez différents types d'animaux ayant un diabète de type 1 et de type 
2. Le traitement au Zn améliore les anomalies du métabolisme des glucides et des lipides. 
Dans les cellules isolées, il rehausse le transport du glucose, la synthèse du glycogène et 
des lipides, et empêche la gluconéogenèse et la lipolyse. 
Il a été démontré que les mécanismes moléculaires responsables des effets Zn, 
comparables à ceux induits par l'insuline, impliquent l'activation de plusieurs composantes 
clés de la voie de signalisation de l'insuline. Celles-ci incluent les extracellular signal-
regulated kinase1l2 (ERK1I2), le phosphatidylinositol 3-kinase (PI3-K), et la protéine 
kinase B (PKB). Cependant, les mécanismes moléculaires par lesquelles le Zn active ces 
voies de signalisation ne sont pas encore très clairs. Bien que les signaux induits par le Zn 
sont associé à la phosphorylation des tyrosines du récepteur de l'insuline (IR), ainsi que 
l'activation de l'Insulin-like Growth Factor-l Receptor (IGF-IR) et de l'Epidermal Growth 
Factor Receptor (EGFR) dans des différents systèmes cellulaires, la contribution spécifique 
de chacun de ces récepteurs protéine tyrosine kinase (R-PTK) dans la médiation de la 
signalisation de ERK 112 et PKB induite par le Zn n'est pas encore établis. De plus, le 
besoin de l'activité PTK du IR dans les effets induits par le Zn reste controversé, et aucune 
preuve pour le rôle de IGF-IR dans ce processus n'a été donnée. Puisque les voies ERK 
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112 et PI3-KlPKB sont responsables pour les effets mitogènes et métaboliques de 
l'insuline, respectivement, l'objectif principal de cette étude est d'étudier le rôle des R-PTK 
dans l'activation de ERK 112 et PKB par le Zn. 
En utilisant des inhibiteurs pharmacologiques, ainsi que des cellules surexprimant 
des formes normales et mutantes de IR et IGF1R, nous avons étudié le rôle de plusieurs R-
PTKs dans la phosphorylation de ERKll2 et PKB induite par le Zn. Nos résultats 
démontrent que le Zn stimule la phosphorylation de PKB et ERKll2 d'une manière dose et 
temps dépendante dans les cellules CHO-IR. Le prétraitement avec AG 1024, inhibiteur de 
IR et IGF1R, bloque la phosphorylation de PKB et ERK 112 en réponse au Zn, mais l'AG 
1478, inhibiteur du EGFR, était sans effet. Dans les cellules CHO surexprimant une forme 
inactive du IR (CHO-1018), le Zn induit toujours la phosphorylation de PKB et ERKll2, 
tandis que la phosphorylation de PKB et ERK1/2 induite par l'insuline est aboli dans cette 
lignée cellulaire. Aussi, la phosphorylation de PKB et ERK 1/2 induite par le Zn est atténué 
dans les cellules IGF1R KO. Ensemble, ces résultats suggèrent que la phosphorylation de 
PKB et ERK 112 induite par le Zn est dépendante de IGF1R-PTK, mais indépendante de 
IR- et EGFR-PTK. 
Mots-clés: Zinc, Agents insulino-mimétique, Récepteur d'insuline, Insulin-like Growth 
Factor-l Receptor, Protein Kinase B, Extracellular signal-regulated kinase 112, Diabètes 
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Abstract 
It has long been known that Zn is crucial for the proper growth and maintenance of 
normal biological functions. Zn also has been shown to exert insulin-mimetic and anti-
diabetic effects. These insulin-like properties have been demonstrated in isolated cells, 
tissues, and different animal models of type 1 and type 2 diabetes. Zn treatment has been 
found to improve carbohydrate and lipid metabolism in rodent models of diabetes. ln 
isolated cells, it enhances glucose transport, glycogen and lipid synthesis, and inhibits 
gluconeogenesis and lipolysis. 
The molecular mechanisms responsible for the insulin-like effects of Zn compounds 
have been shown to involve the activation of several key components of the insulin 
signalling pathways, which include the extracellular signal-regulated kinase1l2 (ERK1I2) 
and phosphatidylinositol 3-kinase (PI3-K) 1 protein kinase B/Akt (PKBJAkt). However, the 
precise molecular mechanisms by which Zn triggers the activation of these pathways 
remain to be clarified. Although Zn-induced signalling has been linked to an increase in 
the tyrosine-phosphorylation of insu lin receptor (IR), as weIl as activation of insulin-like 
growth factor-l receptor (IGF-IR) and epidermal growth factor receptor (EGFR) in 
different cell systems, the specific contribution of each of these receptor protein tyrosine 
kinases (R-PTKs) in mediating Zn-induced ERKll2 and PKB signalling remains to be 
established. In addition, the requirement for insu lin receptor (IR) PTK activity in Zn-
mediated effects is still controversial, and no clear evidence for a role of IGF-IR in this 
process has been provided. Since the ERK 1/2 and PI3-KlPKB pathways are implicated in 
mediating the mitogenic and metabolic effects ofinsulin respective1y, the main objective of 
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this study was to investigate the role ofR-PTKs in Zn-induced ERK 1/2 and PKB/Akt 
activation. By using pharmacological inhibitors, as well as cells that overexpress normal 
and mutant/inactive forms of IR and IGF -IR, we have investigated the role of various R-
PTKs in Zn-induced ERK1/2 and PKB phosphorylation. Zn stimulated ERK1/2 and PKB 
phosphorylation in a dose and time-dependent manner in Chinese hamster ovary cells 
overexpressing IR (CHO-IR). Pretreatment with AG 1 024, an inhibitor for IR and IGF -IR, 
blocked Zn-induced ERKl/2 and PKB phosphorylation, but AG1478, an inhibitor for 
EGFR was without effect. In CHO cells overexpressing tyrosine kinase deficient IR (CHO-
1018), Zn was still able to induce the phosphorylation ERK1/2 and PKB/Akt, whereas 
insulin-induced ERK1/2 and PKB/Akt phosphorylation was abolished in these cells. 
Moreover, Zn had no effect on the tyrosine phosphorylation of IR-p-subunit and IRS-l in 
CHO-IR cells. Furthermore, in IGF-IR knockout cells, both IGF-l and Zn were unable to 
stimulate the phosphorylation ofERK1/2 and PKB. Taken together, these data suggest that 
Zn-induced ERK1/2 and PKB/Akt phosphorylation is independent of IR- or EGFR-PTK, 
but requires IGF-IR-PTK. 
Keywords : Zinc, Insulin signal mimi cry, Insulin Receptor, Insulin-like Growth Factor-l 
Receptor, Protein Kinase B, Extracellular signal-regulated kinase 1/2, Diabetes 
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Chapter 1 - Introduction 
1.1 - Metals and Diabetes: An Odd Pairing 
Diabetes Mellitus is a major global health problem characterised by 
hyperglycaemia, polyurea, polydipsia, and polyphagia (1). Two major fonns of the disease 
exist: Type 1 diabetes, or insulin-dependent diabetes mellitus, fonnerly also known as 
juvenile diabetes, and type 2 diabetes, or non-insulin-dependent diabetes mellitus. 
In type 1 diabetes, there is an uncontrolled autoimmune response against insulin 
secreting pancreatic p-cells, Ieading to the destruction of the latter, and leaving the patient 
with a lack of insulin (2;3). Up to 10% of diabetics suffer from this fonn of the disease, 
and it generally occurs in young and lean patients (4). In type 2 diabetes, pancreatic p-cells 
still produce insulin, however, due to peripheral insulin resistance, there is a decrease in the 
uptake and transport of blood glucose by muscle and liver tissue (5;6). Under these 
conditions, to compensate for the excess glucose in the blood stream, the p-cells increase 
their production of insulin. This overproduction of insu1in results in an increase in the 
pancreatic p-cells mass, which can cause hyperinsulinemia, further exacerbating the insulin 
resistance (7), leading to full fledged type 2 diabetes (8-10). Over 90% of the diabetic 
population suffers from type 2 diabetes. 
According to the World Health Organization, it is estimated that around 171 million 
people world-wide suffered from diabetes mellitus in 2000, and that number may double by 
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the year 2030 (J 1). CUITent treatments, such as daily insu lin injections, in conjunction 
with or independently of other oral anti-diabetic medications, su ch as biguanides, 
sulfonylureas, and thiazolidinediones (TZDs), work to either reduce hepatic glucose 
production, to increase pancreatic ~-cell insulin production and secretion, and to increase 
insulin sensitivity in peripheral tissues (J 2). These medications help patients reach 
euglycaemia, yet are not without their own side effects, namely weight gain, increased LDL 
cholesterol, edema, hypoglycemia and increase of baseline waist circumference (J 3). 
Therefore, newer therapeutic approaches are needed to treat diabetes more efficiently, and 
more cost effectively. 
It has long been known, even before the discovery of insulin, that many metals, as 
weIl as their salt derivatives, possess insu lin mimetic and anti-diabetic effects. For 
example, in 1899, 22 years before the discovery of insulin, sodium orthovanadate 
(Na) V04), a vanadium salt, was shown to decrease glucosuria in two out of three diabetic 
patients (J 4). However, it took almost one cent ury for interest in this area of research to 
peak, when it was shown that multiple vanadium salts were able to stimulate glucose 
transport and oxidation (J 5-18), as well as lipogenesis in adipocytes (J 5-20). These salts 
alsb enhanced glycogen synthesis in the rat diaphragm and hepatocytes (J 5;21 ;22), and 
inhibited gluconeogenesis in the liver (J 5). The demonstrations that Na) V04 was capable 
of norrnalizing hyperglycaemia in animal models of diabetes mellitus (23;24) sparked the 
interest of c1inicians in the metal and it was found that N a3 V04 and vanadyl sulphate (VS) 
were able to improve hyperglycaemia in severallimited human studies (25-30). 
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Molybdenum (Mo) is also a transition metal, in the group VI B, and like 
vanadium, it can exist in multiple oxidation states (five to be exact: 2, 3, 4, 5, and 6), and 
exerts anti-diabetic properties (31;32). Molybdate was found to increase glucose transport 
and oxidation in adipocytes and decrease blood glucose in Streptozotocin-induced diabetic 
rats (33;34), and in a genetically obese, insulin-resistant ob/ob model of mouse (35). 
Molybdate also increased insulin receptor (IR) autophosphorylation, as well as the 
phosphorylation of IR substrate pp160 (36). 
Chromium (Cr) is yet another transition metal with insulin-mimetic and insulin-
enhancing effects. Aiso a group VI trace metal, it is considered an essential trace mineraI 
(37). Cr can exist in four different oxidation states, and due to this, its ions and complexes, 
similar to those of vanadium and molybdenum, take on a variety of beautiful colours. In 
its biologically stable trivalent form, Cr has been shown to improve insu lin response to 
glucose in rats fed a high sucrose-Iow Cr diet, hypothetically by preserving normal 
peripheral tissue insulin sensitivity, and by playing a role in the maintenance of normal ~­
cell glucose sensitivity (38). It has also been shown that insulin-stimulated glucose 
transport was improved by Cr, by increasing the amount of the glucose transporter 4, 
GLUT4, being mobilised to the plasma membrane of adipocytes, as well as increasing 
membrane fluidity by decreasing plasma membrane cholesterol (37). Similar findings were 
shown in vivo, wh en Cr enhanced insulin stimulated GLUT4 translocation, as well as 
insu lin sensitivity and glucose disappearance, and improved the lipid profile in obese and 
insu lin resistant rats (39). 
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Zinc (Zn) is yet another metal with potent insulin-sensitizing and insuIin-
mimicking effects. This work will focus on the insulin-mimetic and anti-diabetic effects of 
Zn, and discuss in detail its chemistry, its role in type l, as weIl as type 2 diabetes meIlitus, 
and its mechanism of action at the molecular level. 
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1.2 - Historical Aspects of Zinc 
Zinc (Zn) is a group 12 trace element, and is the 23rd most abundant element in the 
earths cru st (40). It is the second most common trace metal found in the body, after iron, 
and is the fourth most used metal in the world, after iron, aluminium and copper (41). Zn 
has been used since the time of the ancient Egyptians, in the form of zinc oxide (ZnO), to 
aide in the healing of wounds and bums (42). Jt was also used in later centuries by the 
ancient Greeks and Romans, taken from calamine ores (zinc ores discovered in the Belgian 
city Calamine) in a copper-zinc alloy to produce brass. By the late 1300's, Zn was 
recognised as a new metal in India, and was mined extensively in Zawar, India, for both 
brass production and medicinal purposes. In the western world, the discovery of pure Zn is 
most often credited to the German chemist Andreas Marggraf, when in 1746, he extracted 
Zn by heating calamine ores and carbon together (43). 
In nature, Zn occurs as a lustrous bluish-white met al. It is interesting to note that in 
nature, this trace metal is only present in its divalent state, Zn(IJ). 
In humans, Zn is found in aH tissues and tissue fluids. In an average 70 kg male, the 
total quantity of Zn is estimated to be approximately 2.3 grams, making it the most 
prevalent trace metal found in tissue (only iron is found in higher concentrations in the 
human body at about 4 grams, but is located primarily in blood (44)) Over 75% of this Zn 
is located in skeletal muscle and bone tissue (40). As weIl, apart from iron, zinc is the only 
other element for which nutritional requirements have been established (45). 
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Important sources of Zn are found in most unprocessed food sources, yet Zn 
concentrations may vary greatly from one type of tissue to another, in the same food 
source; for example, lean beef contains 43mg of Zn /kg raw meat, whereas a cut of fat beef 
contains only 10mg/kg raw meat (46). Other important sources of Zn are cheddar cheese 
(40mgIKg), lentils (31mglkg), wholemeal wheat (30mg/kg), although it is also found in 
chicken, rice, pork and sweet corn in moderate quantities (7-20mglkg), and fish, milk, 
potatoes and butter in small quantities (1.5-10mg/kg) (46). 
It has been shown that zinc is essential in growth and development (47) and a zinc 
deficiency has been shown to play a role in multiple diseases, such as malabsorption 
syndrome, sickle cell disease, chronic liver disease and diabetes (48). Zinc deficiency is 
common in developing nations, yet is also observed in a great number of men and women, 
from varying economic classes and cultures, suffering from varying clinical conditions, in 
the United States (47;49). The recommended dietary allowance for zinc is 8mg/day for 
women and Ilmg/day for men (50). 
7 
1.3 - Chemistry of Zinc 
1.3.1 - Inorganic Zinc Compounds 
As stated earlier, Zn is only present in its divalent state, Zn(II) , in nature. It is of 
low to intenuediate hardness (malleable at 100-150 OC), yet is considered a very dense 
metal, at 7.13g/cm3, and is therefore called a heavy metal. Being amphoteric, Zn 
dissolves in both strong alkaline and acidic solutions, and can thus react easily with the 
latter or other inorganic compounds to fonu a variety of salts, all of which are 
nonconducting and nonmagnetic and for the most part, white in colour, with very few 
exceptions, such as chromate (51), which changes colours, from yellow to blue-green, 
depending on its oxidation state. In industry, this metal is mainly used as a protective 
coating over iron and other metals against corrosion, in a process called "galvanizing". 
This protective effect cornes from the elements ease of oxidation, due to the fact that it only 
has two electrons on its outer most shell. It is also extensively used in the construction 
industry to fonu metal alloys, and also as an electrode in dry cell batteries, due to its ability 
ofreducing other metal states (51). 
Zinc oxide (ZnO) is one of the oldest· known inorganic zinc compounds. It is an 
odourless, white/greyish coloured powder. ZnO is soluble in acids and bases, yet not 
soluble in water or alcohols. It is widely used as a pigment in paints, as an absorber of 
ultraviolet light (52), and as a vulcanizing agent in rubber products (53). Other common Zn 
compounds, such as zinc chloride (ZnCh), zinc sulphate (ZnS04), and zinc nitrate 
(Zn(N03)z) are, on the other hand, very soluble in water and alcohols (54). 
1.3.2 - Organic Zinc Compounds 
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In contrast to inorganic Zn compounds, organo-metallic Zn compounds do not exist 
naturally in the environment (41). The latter are synthesized, and are frequently used as 
topical antibiotics and fungicidal lotions (55). Organic Zn compounds can be separated 
into three main groups (56) : 
• Organic Zn halides (R-Zn-X), X being any halogen. 
• Di~organic Zn molecules (R-Zn-R), R being any alkyl or aryl group. 
• Lithium or magnesium Zn compounds (M+R3Zn), M being either lithium or 
magnesium. 
The first organo-Zn compound ever synthesized was Diethyl zinc (C2Hs)2Zn. It was 
also the first ever compound to display a sigma bond between a metal and a carbon 
mole cule (57). It reacts violently with water and catches fire with ease when in contact 
with air, and therefore must be handled under nitrogen. It is for this reason that (C2Hs)2Zn 
is known as a hypergolic fuel, because it ignites on contact with air. These types of 
compounds are often used to propel rockets. Sorne common reactions used ta obtain 
organo-Zn cornpounds are oxidative reactions, like the one used by Frankland and Duppa to 
produce diethyl zinc (57), halogen zinc exchange reactions, and transrnetalation reactions. 
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Many organic ZInC compounds are used for their medicinal or biological 
functions. For example, Zn-etheylene-bis(dithiocarbamate)), also known as Zineb, and Zn-
dimethyl-:-dithiocarbamate, or Ziram, are often used as fungicides to prote ct crop harvests 
from disease and deterioration ,:"hile still in the field, in storage, and during transport 
(58;59). Zinc carbonate, which is a mineraI ore of zinc, is often used in to treat skin 
problems, and zinc caprylate is most often used in ointments as a topical antifungal cream 
(54;60). 
1.3.3 - Zinc in Biological Systems 
It has been know for more than a century that Zn is crucial to the proper growth and 
maintenance of biological systems, wh en Raulin showed for the first time in 1869 that Zn 
was indispensable for the growth of the fungus Aspergillus niger , also known as the black 
mold (61). ft took almost sixt Y years after that discovery to prove that Zn was also essential 
for the growth of higher fonns of plants (62-64). In 1934, it was proven for the first time 
that zinc was not only essential in plant life, but in mammalian life as well, when it was 
shown that Zn deficiency caused growth retardation and loss of hair in the rat (65), as weil 
as in the mouse (66). Later studies showed that multiple other species of animaIs, including 
birds, pigs, sheep, cows and dogs, can aiso suffer from Zn deficiency, which causes 
retardation in growth, 10ss of hair, defonned nails, testicular atrophy, hyperkeratosis, 
conjunctivitis, and skin lesions (67-71). 
Tt was not until 1961 though, that Zn2+ was assigned a biological role in humans 
(72). Tt was discovered by Prasad et al. that a group of adult males from Iran, who were 
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anemlc, yet who also suffered from dwarfism, hepatosplenomegaly and 
hypogonadism, were not only iron deficient, but were also Zn deficient. When given Zn 
containing iron supplements, the anemia was corrected, the hepatosplenomegaly improved, 
there was growth of pubic hair, and an increase in genitalia size (73). Sandstead later 
confirmed that the cause of all the symptoms seen by Pras ad in Iran were due to Zn 
deficiency, and not just iron deficiency (74). He showed that Zn supplementation 
accelerated growth, more than would an iron and protein supplementation alone, in a group 
of Egyptian patients. As well, Zn supplementation initiated puberty within 7 to 12 weeks 
of Zn supplementation in these patients, who were already adults, a phenomenon which 
would come to completion, with full development of secondary sexual characteristics 
between 12 and 20 weeks (74) (Figure 1). 
As stated earlier, Zn is found in most tissues of the human body. It is located 
predominantly in the pancreas, which contains 20 to 30 ~g/ g of tissue, in the liver, which 
contains 40 to 60 ~g/ g of tissue, and in the bone, containing as well 40 to 60 ~g/ g of tissue 
(42). Zn is found in relatively small quantities in the blood, as compared to intracellular 
stores. Zn blood plasma concentrations are on average 12.5 !lM (75), yet can vary from 
10. 7~M, the lower limit of normal (after a moming fast) (76), to 21.1 ~M (77) in healthy 
individuals. 
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Figure 1: Effects of Zinc deficieocy 00 metabolic processes associated with growth. 
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Reduced food intake may be a protective mechanism to allow survival during Zn 
deficiency. AIso, Zn is an integral part of many cellular processes, like growth. Growth 
requires cellular division, as weB as DNA, RNA, and protein synthesis, implicating Zn as a 
cofactor for many enzymes, as weIl as influencing gene expression through transcription 
factors. Furthermore, growth hormone (GH) and insulin-like growth factor-I (lGF-1), 
through reduced food intake and/or Zn deficiency not associated with reduced food intake 
(dashed orange arrow) may negatively affect 1 GF -1, growth hormone binding protein 
(GHBP) and growth hormone receptor (GHR) mRNA levels in an direct fashion (orange 
dashed arrows). This diagram illustrates the relationship between Zn deficiency and 
decreased growth, through several different, but related mechanisms. (inspired from (78)). 
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At the molecular level, Zn is an exceptionally important micronutrient, 
required for over 300 enzymatic reactions that take place in the body (79), and is part of 
more than 2000 Zn dependent transcription factors and other proteins (80). Zinc is present 
in the cell nucleus, nucleolus, and the chromosomes. It plays a vital role in the synthesis of 
DNA and RNA, through zinc metalloenzymes such as RNA polymerase (81), reverse 
transcriptase and transcription factor IlIA (82), and has a stabilizing role in the structure of 
DNA, RNA and ribosomes (82). Zn helps to form certain structures in these 
metalloenzymes, which allow the proper functioning of the latter. The most common 
structure is the zinc finger domain, in which the zinc ion forms a loop in the polypeptide 
chain by creating a bridge between cysteine and histidine residues (78). The zinc finger 
domain in these enzymes was found to be essential for the binding of eukaryotic regulatory 
proteins to specifie DNA sequences (83). More recently, Zn fingers have also been shown 
to bind RNA, as well as being involved in protein-protein interactions, which may help 
explain why there are Zn fingers that do not bind either DNA or RNA (84;85). 
Zn homeostasis is at least, in part, controlled by metallothionein. Metallothioneins 
(MT) are small proteins (approx. 6200Da) rich in cystein, with a very high affinity for 
divalent heavy metal ions, such as cadmium, mercury, platinum, silver and Zn (86;87). MT 
are primarily found in the liver, pancreas, kidneys and intestinal mucosa. In this sense, they 
help protect cells and tissues against heavy metal toxicity, facilitate the exchange of metals 
functioning as anti-oxidants in tissues, as well as protecting the cell against hydroxyl free 
radicals, which can cause an oxidative stress induced apoptosis (87;88). It has been 
suggested that MT play an important role in Zn-induced cell proliferation and 
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differentiation (89), since they are over expressed in proliferating tissues, such as 
regenerating and developing rat livers, and certain types oftumors (90-93). MT also play a 
role in metal exchange with Zn dependant enzymes, such as carbonic anhydrase (CA), a 
zinc metalloenzyme that catalyzes the reversible conversion between carbon dioxide and 
the bicarbonate ion, tlrrough the hydration of carbon dioxide (C02) (94-96). CA, and by 
association, Zn, is therefore involved in vital physiological pro cesses liked with respiration, 
transport of CO2 / bicarbonate between lungs and tissues, pH and C02 equilibrium, 
ureagenesis, gluconeogenesis, and lipogenesis, (97-99) the latter two linking Zn to diabetes 
and its insulino-mimetic effects, which will be discussed later in this text. 
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1.4 - Zinc and Diabetes 
In 1980, it was shown for the first time that Zn, in the form of zinc chloride (ZnClz) 
can mimic insulin in its ability to stimulate lipogenesis in rat adipocytes (100), ev en though 
a connection between Zn and diabetes had been made 14 years earlier, wh en Quarterman et 
al. demonstrated that Zn deficient animaIs were less sensitive to insulin, causing them to 
conc1ude that Zn was in sorne way involved with insulin action (101). The fact that it was 
already known that Zn is stored in and secreted from the pancreas along with insulin (102), 
as well as Zn being inc1uded in insu lin preparations, prompted investigators to test the anti-
diabetic potential of Zn in animal models of diabetes. 
1.4.1 - Zinc and Animal Models of Type 1 Diabetes 
In animal studies, subcutaneous Zn injections were shown to partially prevent 
hyperglycaemia and development of diabetes in streptozotocin (STZ) treated rats, through 
the increased activation of MT acting as an oxygen free radical scavenger, as well as a 
reductant of lipid peroxidation in the pancreas and liver (103). It should be noted that 
animaIs treated with STZ, a compound that specifically destroys insu lin producing p cells 
of the pancreas, are considered a good model of type 1 diabetes mellitus (104). Later 
studies proved that these effects were not entirely due to the increased activation of MT, as 
Zn pre-treatment of STZ-induced diabetic MT-null mice improved their diabetic state 
(105). 
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The aforementioned studies were confirmed by Ohly et al. The latter gave 
C57BL/6 mice multiple low doses of STZ (MLD-STZ) to induce diabetes. Mice were then 
given Zn (in the form of zinc sulphate)-enriched drinking water, and it was shown that the 
Zn-enriched drinking water up-regulated MT, as weIl as prevented MLD-STZ diabetes and 
108S of pancreatic ~-ceIl function (106). The MLD-STZ mice treated with Zn-enriched 
drinking water had a significant decrease of their blood glucose concentrations, and 
maintained a blood glucose concentration under the euglycaemic threshold of 13.9 mmolll, 
while the non-Zn treated MLD-STZ mice had blood glucose concentrations much higher 
than the euglycaemic threshold. Furthermore, following the results of an oral glucose 
tolerance test, it was shown that Zn-enriched drinking water significantly countered MLD-
STZ loss of glucose tolerance, an indicator .that Zn treatment prevented essential ~-cell 
dysfunction. The group went on to conclude that these anti-diabetic effects were due to the 
activation of Zn-induced MT, which provides a defense against OH- groups generated in ~­
cell by the inflammatory reactions, most probably due to the MLD-STZ treatment (106). 
In further support of the anti-diabetic effects of Zn, Tobia et al. showed that high Zn 
supplementation (HZn) (1000 ppm) dramaticaIly delayed the onset and reduced the severity 
of diabetes in BioBreed (BB) W~star rats, an inbred rat strain that spontaneously develops 
diabetes, as compared to BB rats fed a normal Zn diet (NZn) (50 ppm), and low Zn (LZn) 
(1 ppm) (107). The study demonstrated that the NZn and LZN groups became diabetic 
almost two weeks before the first HZn became diabetic, at 85 days of age. At 100 days of 
age, only 19% of the HZn became diabetic, as compared to 53% for the NZn group and 
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44% for the LZn group, which equates to a 60% drop in the onset of diabetes. Also, 
the HZn group had improved glucose tolerance, which can be justified by the higher serum 
and pancreatic insulin content, as weIl as increased insu lin release, compared to the animaIs 
in the other two groups (lO7). 
1.4.2 - Zinc and Animal Models of Type 2 Diabetes 
The anti-diabetic potential of Zn compounds has also been examined in animal 
models of type 2 diabetes mellitus. In 1985, Begin-Heick et al. showed that a high Zn 
supplementation (lOOOmg ZnlKg diet) for 4 weeks attenuated fasting hyperglycaemia and 
hyperinsulinemia in ab/ab mice (l08), a weIl established model of type 2 diabetes mellitus. 
In these studies, high Zn supplementation elevated insulin in pancreatic islets, and 
attenuated of the abnonnally high insulin secretory response to glucose in isolated 
pancreatic islets (J 08). 
It was later shown that ev en a lower dose of Zn (300 ppm) for 6 weeks was 
sufficient to decrease fasting hyperinsulinemia and hyperglycaemia, as weIl as in reducing 
the amount of body weight in db/db mice, another mou se model of type 2 diabetes (J 09). 
Furthennore, in the same 6 week time span, a Zn deficient diet (3 ppm) aggravated fasting 
hyperglycaemia in db/db mice, compared to those fed a diet adequate in Zn content (30 
ppm). Zn supplementation àlso increased pancreatic Zn content of ab/ab mice to normal 
levels (J 09). It was therefore conc1uded that a high pancreatic Zn content and low 
circulating insu lin levels due to Zn supplementation in db/db mice enhanced peripheral 
insulin sensitivity and pancreatic ~-cell function, and as a result, less circulating 
insulin was necessary to invoke glucose uptake (109). 
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In yet another recent study, a complex formed between Zn and Cyclo (His-Pro) 
(CHP), a metabolite of thyrotrophin-releasing hormone or product of peptide or amino acid 
sources, was studied in the Goto-Kakizaki (GK) rat, a non-obese type 2 diabetes animal 
model, exhibiting a mild fasting hyperglycaemia (110). CHP metabolism is thought to be 
directly related to glucose metabolism (110), since STZ-diabetic rats exhibited an increase 
of CHP levels which decreased after insulin treatment (111), suggesting that blood glucose 
metabolism is related to gut CHP concentrations (I12). The Zn-CHP compound was 
shown to improve short term and long term oral glucose tolerance, as weIl as decreased 
insulin resistance, in aged GK rats (110). This decreased insulin resistance is thought to be 
due to the supply of new Zn brought into the system through the Zn-CHP complex. Zn 
then becomes part of new enzymes and proteins that remove partially digested protein 
fragments from the ceIl, and goes on to increase synthesis and translocation of GLUT 4 
(110). The integration of Zn into the system happens through its chelation by CHF, causing 
its increased intestinal absorption and uptake in muscle tissue (113), hence increasing Zn 
metabolism. 
1.4.3 - Organic Zinc Complexes and Diabetes 
In most of the studies using Zn as an anti-diabetic molecule, either a high dose of Zn 
(lOOOppm) (10l) or a long treatment period (up to 8 weeks) (114) was used , both ofwhich 
may be toxic to the organism being treated. At the time, it was discovered that Bîs-
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maltolato-oxo-vanadium (BMOV), an organo-vanadium compound, was more potent 
than inorganic vanadium salts in improving hyperglycaemia in STZ-diabetic rats (1 J 5). 
This discovery prompted Sakurais' group to synthesize Bis-maltolato-Zinc (II) (Zn(Mal)2), 
which was modeled after BMOV (1 J 6). This compound, at 500 flM, was found to inhibit 
free fatty acid release from epinephrine-stimulated rat adipocytes to a greater extent than 
VOS04 and ZnS04 (1 J 6). It was also shown that Zn(Ma1)2 inhibited free fatty acid release 
from epinephrine-stimulated rat adipocytes to a greater extent than insulin or Zn(Mal)2 
alone, suggesting that this compound was not only an insulinomimetic compound, but also 
an insu lin enhancer (1 J 7). 
In animal experiments, using insulin-resistant KK-AY type 2 diabetic mice, it was 
observed that intraperitoneal (i.p.) injection of 68.8 flM Zn(Mal)2 /Kg body weight for the 
first two days decreased blood glucose from above 20mM to just under 11mM, which was 
maintained at that level for two weeks (1 J 7). After two weeks of treatment, serum insu lin 
and triglyceride levels dramatically improved in treated mice, as compared to a non-treated 
KK-AY control group. AIso, blood urea nitrogen, an indicator of renal disturbance, 
glutamic oxaloacetic transaminase, and glutamic pyruvic transaminase, indicators of liver 
disturbance, were unchanged in treated mice, as compared to non-treated KK-AY control 
group (1 J 7), showing that Zn(Ma1)2 did not disturb renal or hepatic functioning. 
Furthermore, oral glucose tolerance tests after the two week treatment showed greatly 
improved glucose tolerance in KK-AY- Zn(Mal)2 treated group (1 J 7). 
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Subsequently, several new organic Zn compounds were synthesized and were 
tested for their anti-diabetic potential. Two such compounds, Bis(picolinato)zinc(II), 
Zn(pich, and Bis(methylpicolinato)zinc(II), Zn(mpa)2 were synthesized by Yoshikawa et 
al. (118). Results of tests do ne in isolated rat adipocytes and in KK-AY type 2 diabetic mice 
were similar to tests done using Zn(Mal)2 (117), with the difference that Zn(mpa)2 was 
found to be more potent than Zn(Mal)2 and Zn(pich. Zn(mpa)2 was shown to improve 
cholesterol metabolism and decrease HbAIC, or glycosylated hemoglobin, an indicator of 
glycaemic control (J 19; 120), to a greater extent than Zn(Malh, Zn(pic )2, VOS04 and 
ZnS04, while exhibiting no alteration in hepatic and renal functions (118). 
Since then, many other organic Zn compounds have been synthesized, such as bis 
(allixinato)Zn(II), ZN(alx)2 (J 21), bis(2-aminomethyl-pyridinato)Zn(II) (122), bis 
(dimethyldithiocarbamate)Zn(II) and bis (diethyldithiocarbamate)Zn(II) (123), aIl of which 
have exhibited potent insulinomimetic and insulin enhancing properties in in vitro as weIl 
as in vivo experiments (figure 2). Not only are these compounds more potent than their 
predecessors, but also improve complications of diabetes, such as improving obesity-linked 
hypertension in mice, hyperleptinemia, as weIl as adiponectine serum levels (123), which 
were shown to play a protective role against insulin resistance (124). AIso, in early 2007, it 
was shown for the first time that bis(pyrrolidine-N-dithiocarbamate)Zn(II), Zn(pdch, 
improved glucose tolerance and had a hypoglycaemic effect in KK-AY mi ce through oral 
administration, and notjust through i.p. injections (123). 
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The preCise mechanism by which Zn and its compounds improve 
hyperglycaemia and glucose homeostasis in diabetes remains unc1ear. However, the ability 
of Zn compound to increase glucose transport, glycogen synthesis, and lipogenesis, and to 
inhibit gluconeogenesis and lipolysis, and to modulate key elements of the insulin 
signalling pathway(J 25-132) have been suggested to contribute to this response. Since 
activation of insulin-induced signalling cascade is critical to exert on insulin-like effect, it is 
important to discuss this pathway in detail. 
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Figure 2: Structure of several organo-Zn compounds exhibiting anti-diabetic effects. 
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1: bis(allixinato )Zn(II), 2: bise ethylmaltolato )Zn(lI), 3: bis(maltolato )Zn(lI), 4: bis(3-
hydroxypyronato )Zn(Il), 5: bis(koj ato )Zn(II), 6: bis(picolinato )Zn(I1). (Inspired trom 
(121; 133)) 
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1.5 - The Insulin Signalling Cascade 
Insulin is the primary hormone involved in blood glucose control. In response to 
increasing blood glucose levels, pancreatic ~-cells secrete insu lin, which stimulates glucose 
uptake in muscle and fat tissues (134) and triggers inhibition of gluconeogenesis and glucose 
release by the liver. 
The first event in insu lin action involves the binding of insulin to its receptor. The 
insu lin receptor (IR) is composed of two extracellular a-subunits and two transmembrane ~­
subunits linked to each other by disulfide bonds (135) (Figure 3). Both the a- and ~- subunits 
are derived from a single proreceptor by proteolytic processing in the Golgi apparatus. The 
a-subunit is located entirely outside of the cell and contains the insulin-binding site, while the 
intrinsic insulin-regulated tyrosine kinase activity possessing ~-subunit is the intracellular 
component of the receptor. The IR-~ subunits consists of five main regions. The first region 
consists of short extracellular sites for glycosylation. The transmembrane region, composed 
of 23 amino acids, anchors the IR to the plasma membrane. The intracellular region, which is 
separated into 3 distinct functional regions, has protein tyrosine kinase activity required for 
insu lin action. It is separated into the juxtamembrane region, containing two tyrosine 
residues, which are autophosphorylated in response to insu lin binding. Of these, tyrosine 972 
is instrumental in binding the phosphotyrosine binding domain (PTB) domains of Insulin 
Receptor Substrate-l (IRS-l) and Shc (135). The regulatory domain (Tyr 1146, Tyr 1150 and 
Tyr 1151), contains adenosine triphosphate (ATP)-binding domains, as well as the enzymatic 
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active site of the receptor, and the C teIminus domain(Tyr 1316 and Tyr 1322), not 
critical for receptor activation, yet is thought to bind Insulin Receptor Substrate-2 (IRS-2) and 
to play a regulatory role that is essential for signalling (135). 
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Figure 3: Schematic representation of the structure of the insulin receptor 
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The insulin receptor, composed of two a-subunits and two ~-subunits, linked by disulfide 
bonds. The extracellular a-subunits contain the insulin binding domains. The transmembrane 
~-subunit has severa! tyrosine autophosphorylation sites, A TP binding domain and regulatory 
region, necessary for the activation of its intrinsic prote in tyrosine kinase activity. (Inspired 
from (J 36)). 
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Binding of insulin to the a-subunit of IR causes a confonnational change, leading 
to an enhanced protein tyrosine kinase (PTK) activity of the p-subunit by multi-site tyrosine 
phosphorylation (137). IR can then phosphorylate several scaffolding proteins, inc1uding 
insulin receptor subtrates (IRSs), Src homology collagen (Shc) and adaptor protein with 
pleckstrin homology (PH) and Src homology 2 (SH2) domains (APS) (138). These 
phosphorylated scaffolding proteins th en bind and activate other signalling kinases, initiating 
several different pathways which mediate the multiple effects of insulin. Zn has been shown 
to phosphorylate IR-P subunit in 3T3-Ll fibroblasts, as well as in rat adipocytes (139). This 
may be one of the possible mechanisms through which Zn exerts its insulin-mimetic effects, 
since activation of IR leads to activation of the insulin signalling cascade (Figure 4). 
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Figure 4: Schematic model showing key elements orthe insulin-signaling cascade 
lnsulin-induced tyrosine phosphorylation and activation of IRJIRS leads to recruitment of SH-
2 domain-containing signalling proteins, such as Grb-2-S0S and the p85 regulatory subunit of 
PB-K, initiating 2 signalling pathways. One pathway, known as the MAPK pathway, 
consists of RaslRafi'MEKlERKl/2 and p90rsk. Another pathway involves PI3-K activation, 
which results in the generation of PIP3. PIP3 activates a variety of downstream signalling 
components involved in a glucose transport system, protein and glycogen synthesis (inspired 
from (140; 141)). 
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In one pathway, IRS-l with growth factor receptor binder-2 (Grb-2) compIexed 
with mammalian son of sevenless (mSOS) results in the activation of Ras and Raf, 
serine/threonine kinases. Activated Raf phosphorylates MEK (MAPK kinase), which in tum 
phosphorylates extracellular signal-regulated kinase (ERKI/2) on Thr and Tyr residues 
located in the activation Ioop of the kinase. ERKI/2 then phosphorylates and activates a 
downstream ribosomal protein kinase, p90rsk• Both ERK1I2 and p90rsk can be translocated to 
the nucleus, where the y phosphorylate transcription factors, such as c-Jun, CHOP, CREB and 
MEF-2 (reviewed in(142)), and contribute to the mitogenic and growth-promoting effects of 
insulin (reviewed in (143)) (Figure 5). 
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Figure 5: Schematic diagram showing key steps involved in insulin-induced activation 
ofERK1I2 
In response to insulin, Shc or IRS-I become phosphorylated and bind the Grb2-S0S 
compIex, Ieading to p2I-Ras stimulation by GTP loading, with subsequent activation of 
Raf, MEK, and two isozymic forms ofMAPK, ERK-l and ERK 2. Both ERKI/2 and and 
other transcription factors can be translocated to the nucleus, activating transcription and 
other cellular processes. (lnspired from (142; 144; 145)). 
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In the other main pathway mediated by insulin action, the p85 subunit of 
Phosphatidylinosito 1 3- Kinase (PI3-K) activates the plI 0 catalytic subunit of PI3-K 
catalyses phosphorylation of phosphatidylinositol (PI) lipids at position 3 of the inositol 
ring, and generates 3-phosphorylated fonns of PI, such as phosphatidylinositol 3, 4, 5 
triphosphate (PIP3) and phosphatidylinositol 3, 4 diphosphate (PIP2) (J 46). The fonnation 
of PIP2 and PIP3 generates recognition sites for Plecstrin Homology (PH) domain 
containing proteins, principaUy 3' -phosphoinositide-dependent kinase 1 (PDK1), which is 
translocated to the plasma membrane along with Protein Kinase B (PKB) (J 46; 147), and 
other and related serine/threonine protein kinases, which are responsible for the 
phosphorylating and activating several downstream signalling protein kinases, su ch as 
PKB, protein kinase C-zeta (PKC-Ç), and p70 ribosomal S6 kinase (p70s6k) (J 48; 149) 
(Figure 6). 
The following sections wiU briefly describe sorne of the key components of the 
insulin signalling cascade, of which the insulin receptor has already been described earlier. 
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Figure 6: Schema tic representation of PKB activation and its physiological role 
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Phosphorylated IRS-I recruits PI3-K, which catalyzes the phosphorylation of PIP2 leading to 
the formation of PIP3. PIP3 recruits PH domain containing proteins to the plasma membrane 
inc1uding PDK-l/2 and PKB, where PKB becomes phosphorylated and activated. PTEN, a 
lipid phosphatase, dephosphorylates PIP3 to PIP2 and thus inhibits activation of PKB. 
(Inspired from (J 50-152)). 
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1.5.1 - Insulin Receptor Substrates 
IRS proteins serve as docking sites for effector molecules responsible for transmitting 
the insulin signal (153). At least four main IRS proteins have been identified in mammals. 
IRS~ 1 and IRS-2 are widely expressed in all tissues. IRS-3 is present in rodents and is highly 
restricted to adipose tissues. IRS-4 is only expressed in the brain, thymus, kidney and P-cells 
(154; 155). IRS proteins are corpposed of a NH2-terminal PH and PTB domain, followed by a 
COOH-terminal tail composed of multiple tyrosine and serine/threonine phosphorylation site 
residues (140;153). 
PTB domain mediates interactions of IRSs with the IR, insulin-like growth factor type 
1 receptor (IGF-IR) and interleukin-4 (IL-4) receptors through phosphorylated-NPXY motifs 
located in these receptors (J 56). The tyrosine phosphorylated residues in the COOH-terminal 
serve as docking sites for SH2 domain-containing signal transducers, such as the p85 subunit 
of PB-K, the SH2 domain-containing tyrosine phosphatase (SHP2) and Src-like kinase Fyn 
(J 57). Adaptor molecules, such as Grb-2, nck, Crk, SHB and others that mediate downstream 
signaIs can also dock in the COOH-terminal (reviewed in (153)). The function of 
serine/threonine (ser/thr) phosphorylation sites in IRSs has not yet been fully understood, but 
several studies have indicated that insu lin resistance inducing factors, such as free fatty acids, 
lead to increased ser/thr phosphorylation of IRS-l and consequently to impairment of insulin 
signal transduction (158). 
Although IRSs are similar in composition, it has been shown that each type has a 
specific role. For example, mice in which IRS-1 has been knocked out have a decreased 
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growth, and suffer from insulin resistance, yet do not develop diabetes (159). On the 
other hand, mice in which IRS-2 has been knocked out develop type 2 diabetes, have a 
decreased ~-cell function, and are insulin resistant (160). In experiments using 3T3-Ll 
fibroblasts and rat adipocytes, Zn treatment was not able to increase tyrosine phosphorylation 
of either IRS-l or IRS-2 (139). As mentioned earlier, activation of PI 3-kinase caused by 
insulin is via the association of tyrosine-phosphorylated IRS proteins with the p85 subtmit of 
PI 3-kinase, yet IRS-l and IRS-2 may not play an important role in Zn induced PI3K1PKB 
activation. 
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1.5.2 - Phosphatidylinositol3-Kinase (PI3-K) 
PI3-Ks are a family of lipid kinases that phosphorylate the D3 hydroxyl group (3' -OH) 
of the inositol ring in phosphatidyl inositol (PI) (143). Products of the PI3-K reaction include 
phosphatidylinositol-3-monophosphate (PIP), phosphatidylinositol-3,4-bisphosphate (PIP2) 
and phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) (161). 
Based on sequence homology and substrate preference, PI3-Ks have been divided into 
classes l, II and III. Class l PI3-Ks are heterodimeric proteins, each of which consists of a 
110 kDa catalytic subunit and an associated regulatory subunit. This class is further divided 
into classes lA and lB, of which class lA has three isoforms (a, ~ and 8) of the catalytic p 110 
subunit and several forms of regulatory subunits (p85a, p55a, p50a, p85~ and p55y). Class 
lB, on the other hand, has only one member of the catalytic subunit called plI Oy and one 
form of the regulatory subunit plO 1. Class lA is activated by receptor PTK (RPTK), while 
class lB is activated by heterotrimeric G protein-coupled receptor (GPCR) (162). In vitro, PI, 
Pl4 P, and PI 4,5 Pare phosphorylated by class l PI3-K enzymes to form PIP, PIP2 and PIP3, 
yet phosphorylation of PI 4,5 P is favoured in vivo, which is responsible for the formation of 
PIP3 (162; 163). 
Class II PI3-Ks, consisting of two major mammalian subclasses, a and ~, contain a 
carboxy-terminal C2 domain, a protein module originally observed in PKC molecules, with 
phospholipid binding sites. There are no known regulatory subunits in this class, which may 
not ev en be necessary. 
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Class III PI3-Ks are thought to represent the primordial PI3-K that gave existence 
to the other classes, due to the fact that it is the only c1ass ofPI3-K enzymes present in yeast. 
PI is the only substrate recognized by this class and is phosphorylated to generate PI3P 
(164; 165). Class III PI3-Ks induce local increases in PI3P, which are thought to be required 
for agonist-independent membrane trafficking processes (165). 
PI3K derived PIP2 and PIP3 bind to the PH domains of downstream targets, such as 
PDKIIPDK2, which are translocated to the plasma membrane, and participate in the 
activation of PKB. Direct stimulation of PI3K by Zn was shown in HNN8 cells (128) and 
Swiss 3T3 celIs (129). 
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1.5.3 -Protein Kinase BI Akt (PKBI A kt) 
PKB was discovered as an oncogene within the mouse leukemia virus AKT8 (166). 
Sequence analysis of the viral oncogene and its cellular homologue revealed that it encodes 
a Ser/Thr kinase (167). PKB is a 57 kDa protein, and was finaUy given the name PKB due 
to its high homology with protein kinase A (PKA) and PKC. It is known to exist as three 
isoforms, PKBa/Aktl, PKBP/Akt2 and PKBy/Akt3 (168). AU PKB isofonns have an 
amino-terminal PH domain, a central catalytic Ser/Thr kinase domain and a carboxy-
tenninal regulatory domain that contains the hydrophobic motif (HM) (150; 169). The PH 
domain of PKB interacts with membrane lipid products, such as PIP2 and PIP3, produced 
by PI3-K (170). The kinase domain of PKB is very similar to other cAMP-dependent/ 
cGMP-dependent/PKC (AGC) kinases, such as PKA, PKC, p70S6K and p90rs\ containing 
the conserved Thr residue whose phosphorylation is required for enzymatic activation 
(150). The carboxy-tenninal regulatory domain of PKB is composed of approximately 40 
amino acids. Phosphorylation of the Ser or Thr residue in this HM is necessary for full 
activation. This motif is identical in an mammalian PKB isofonns, and is of great 
importance, as it has been shown that a deletion mutant motif completely abolishes PKB 
enzymatic activity. 
Phosphorylation site mapping of PKB from quiescent cells with no stimulation, or 
serum starved cells stimulated wÎth IGF-I revealed that while Ser 124 and Thr 450 are 
constitutively phosphorylated and seem to contribute to stabilization of the proteins, 
phosphorylation of Th308 in the activation loop and Ser 473 in the carboxy-tenninal site is 
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detected in stimulated cells (169; 171). Also, the constitutive localization of PDK-l at 
the plasma membrane is thought to be because C terminal PH domain in PDK-l binds 
phospholipids with lü-fold higher affinity than the PKB PH domain. The following 
scenario for PKB activation has therefore been proposed (150;151;172): The activation of 
PI3-K leads to the production ofPIP2 and PIPJ . These phospholipids interact and cause the 
translocation of PKB to the inner membrane, where PDK-I is located. Additionally, it is 
thought that binding of 3' -phosphoinositides to PKB changes its conformational status, 
making the regulatory residues more accessible to phosphorylation. PDK-l, which is 
thought to be constitutively active, phosphorylates Thr308 in PKB (173), stabilizing the 
activation loop in an active form. This phosphorylation is a prerequisite for kinase 
activation, but phosphorylation of Ser 473 is necessary for full PKB activation. The nature 
of putative Ser 473-PKB kinase called PDK-2 is still controversial (174), although several 
candidates have been suggested (175) 
PKB contributes to a variety of cellular responses, inc1uding cell growth, cell 
survival and metabolism. It also plays a primordial role in the mediation of glucose 
transport, glycogen synthesis, gluconeogenesis, lipogenesis, and protein synthesis, through 
the following mechanisms: Increasing the number of GLUT4 transporters available for 
glucose uptake (172;176;177), by activation of Glycogen Synthase (GS) via 
phosphorylation of GSK-3 by PKB on Ser 9 resulting in the inhibition of its catalytic 
activity, increasing glycogen synthesis (178), by suppressing glucocorticoid and cAMP 
signaling-stimulated glucose production by dowmegulating the transcription ofPEPCK and 
G6Pase, as we11 as phosphorylation of FOXOI, to dowmegulate gluconeogenesis 
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(179;180), and by activation ofmTOR (mammalian target of Rapamycin), a 4E-BPl 
kinase, which deactivates 4E-BPI, releasing eIF-4E, promoting translation initiation (151). 
Zn has been shown to activate PKB in BEAS-2B human bronchial ceIls(181), 
HepG2 cells (131), as weIl as in 3T3-LI fibroblasts and rat adipocytes (139). The activated 
PKB contributes to· the regulation of glucose transport, glycogen synthesis, 
gluconeogenesis, lipogenesis, and protein synthesis, through the activation or inhibition of 
downstream effectors, as mentioned earlier. Zn -induced GSK-3 and FOXOI 
phosphorylation has also been shown (131), which may mediate the response of Zn on 
increased glycogen synthesis by upregulation of GS, and inhibition of gluconeogenesis 
(182) 
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1.5.4 - Mitogen Activated Protein Kinase (MAPKJERKl/2) Pathway 
MAPKs are a family of Ser/Thr protein kinases, which have been widely conserved 
among eukaryotes. They are involved in cell proliferation, cell differentiation, cell movement 
and cell death, amongst other cellular responses (142; 144; 183; 184). 
In mammalian cells, five MAPK families have been identified, inc1uding ERKl, 2, 5, 
7, Jun N-terminal kinase 1,2 and 3 (JNK1I2/3), and p38a, p, y, and 8. These pathways all 
follow a similar system of activation, in which a stimulus activates a MAPKKK, which will 
then activate a MAPKK, which is an upstream activator of MAPK, which leads to a cellular 
response. The MAPK is the final effector of the cellular response. MAPKKKs are Ser/Thr 
kinases, and are activated through phosphorylation and/or as a result oftheir interaction with a 
small GTP-binding protein of the RaslRho family in response to extracellular stimuli. 
Activation of MAPKKKs phosphorylate and activate MAPKK, which then phosphorylates 
Thr and Tyr residues in the activation loop of the kinase, stimulating MAPK activity. Once 
activated, MAPKs phosphorylate target substrates on Ser or Thr residues followed by a praline 
(figure 5). 
ERK1I2 is the principal MAPK pathway activated by insulin. This pathway consists 
of the MAPKKKs (A-Raf, B-Raf and Raf-l), the MAPKKs (mitogen and extracellular signal 
regulated kinase 1 and 2 (MEK1I2)), and the MAPKs (ERK-l and ERK-2). SignaIs from 
activated receptor tyrosine kinase (RTK) or GPCR to Raf/MEKIERK are transmitted through 
different isoforms of the small GTP-binding protein such as Ras. As mentioned earlier, 
following activation of the IR and its substrates, Grb-2 associates with SOS, and this causes 
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the release of GDP, as well as binding of GTP to Ras (forming Ras-GTP), which is 
accompanied by a conformation change in Ras, allowing it to bind to a wide range of 
downstream effector proteins, including isoforrns of the Ser/Thr kinase Raf. Raf then binds 
to, and phosphorylates, the dual-specificity protein kinase MEK-l and -2, the latter of which 
phosphorylate ERK1/2 within a conserved Thr-Glu-Tyr (TEY) motif in their activation loop. 
ERKl/2 can then be translocated to the nucleus where it can phosphorylate and activate a 
number of transcription factors involved in gene activation. It can also activate a number of 
cytosolic proteins, such as p90rsk through its proline directed Ser/Thr kinase activity. 
Zn was shown to activate ERK1I2 in HT-29 colorectal cancer cells (125; 127), as weIl 
as in human epidermal A431 cells, which leads to activation of the mitogenic effects of the 
insulin signalling cascade, namely cell growth and gene transcription. This activation by Zn 
has been suggested to function through both a epidermal growth factor receptor -dependent 
and -independent pathway (126). 
1.5.5 - Protein Tyrosine Phosphatases (PTPases) Implicated in the 
Insulin Signalling Cascade 
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PTPases are important regulators of the insu lin signalling pathway. They catalyze the 
rapid dephosphorylation and inactivation of IR-P subunit and IR substrates (185). PTPases 
can be divided into four classes: 1) classical receptor PTPases (R-PTPases), which include 
leucocyte antigen receptor (LAR), PTPo-, PTPo (type lia); PTP~, PTPK, PTPÂh,jJ/o (type lib); 
PTPcp; PTPa, PTPE (type IV); PTPÇ/P, PTPy (type V); 2) classical non-receptor PTPases 
(NR~PTPases) including PTP1B, SHP-1, SHP2, PTP-PEST; 3) dual specificity PTPases (DS-
PTPases); and 4) low molecular weight PTPases (186;187). R-PTPases and NR-PTPases are 
specifie only to phosphotyrosine residues, whereas DS-PTPases recognize phosphotyrosine, 
phosphopthreonine and phosphoserine residues. 
PTP1B was the first PTPase isolated and characterized in detail from the human 
placenta (188). Because a decrease in its expression level resulted in increased insulin 
signalling and action, PTP1B has been considered as a negative regu1ator of insu lin action 
(189). For example, glucose transport and GLUT -4 translocation are decreased in PTP1B-
overexpressing cells (189), and osmotic loading of neutralizing PTP1B antibodies in rat 
hepatoma cells increased insulin-induced IRS-1 phosphorylation, PI3-K activity and DNA 
synthesis (190). AIso, a role of PTP1B, and other PTPases has been suggested in the 
pathogenesis of diabetes, because PTPase expression has been shown to be impaired in rodent 
models of type 1 and type 2 diabetes mellitus, as well as in human subjects (191-194). 
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LAR, a type of R-PTPases, is widely expressed in insulin-sensitive tissues (195). 
Treatment of cells with insulin results in increasing association between LAR and IR. In the 
plasma membrane, LAR physically interacts with the IR and promotes its dephosphorylation 
(196) Furthermore, fat tissue of obese patients, as well as 3T3-Ll adipocytes pre-incubated 
with high glucose, show high LAR expression levels (192). 
SHP2 (also called PTPID, SH-PTP2, SH-PTP3, Syp and PTP2C) is a ubiquitously-
expressed cytosolic PTPase (197), composed of a central phosphatase domain, two amino-
terminal SH2 domains and a carboxy-terminal tail containing two tyrosyl phosphorylation 
sites (186). Overexpression of dominant negative SHP2 in rat adipocytes impairs insu lin-
induced GLUT -4 translocation. It also blocks insulin-stimulated mitosis in 3T3-Ll 
adipocytes and insulin-induced Ras activation. In contrast, disrupting binding between IRS-l 
and SHP2 results in increased the Tyr phosphorylation of IRS-l and heightened insulin-
dependent activation· of PI3-K as well as protein synthesis but this mutation fails to alter 
MAPK activity and cell proliferation (reviewed in (186»). 
It has been shown that the enzymatic activity of PTPIB is inhibited by Zn in C6 rat 
glioma cells (198), as well as in airway epithelial cells (199), which can potentially increase 
the phosphorylation of IR, or other R-PTKs, through inhibition of its dephosphorylation. 
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1.5.6 - PTKs Other than the IR as Potential Targets of Zinc 
As mentioned earlier, Zn has been shown to potently inhibit PTPs (198-200), induce 
tyrosine phosphorylation of insu lin receptor-~ subunit (IR-~) (139), and activate the 
PI3K1PKB pathway (128;129;131;139), all integral parts of the insu lin signalling cascade. In 
addition, Zn has alsobeen shown to induce the tyrosine phosphorylation of epidermal growth 
factor receptor in A431 human epidermal carcinoma cells, B82 mouse lung fibroblasts, and 
primary HAE cells (126;201;202), as well as cause IGF-IR-~ subunit phosphorylation in C6 
glioma cells (198). Therefore, it is possible that Zn-induced signalling responses may be 
mediated through the activation of growth factor receptor-PTKs, which we will examine here. 
1.5.6.1 - Epidermal Growth Factor Receptor (EGFR) 
The EGFR is a receptor tyrosine kinase that is ubiquitously expressed in a variety of 
cell types, and is most abundant in epithelial cells and many cancer cells (203-205). It 
belongs to a family containing three other members (ErbB2, ErbB3, and ErbB4) that undergo 
homodimerization or heterodimerization to induce autophosphorylation and receptor tyrosine 
kinase activation in response to ligand binding (204;206). The EGFR contains an 
extracellular ligand binding domain, a single transmembrane domain and a cytoplasmic 
tyrosine kinase autophosphorylation and regulatory domain. Dimerization of the receptor 
activates the intrinsic tyrosine kinase activity of the intracellular domain at different residues, 
resulting in the recruitment of the SH-containing domain proteins, which trigger downstream 
events. The phosphorylation ofEGFR on tyrosine 1068 is followed by recruitment of the 
adaptor protein Grb2, leading to the activation of RasIERK1I2 pathway. 
1.5.6.2 - Insulin-like Growth Factor type 1 - Receptor (IGFI-R) 
44 
IGF-IR is also a receptor tyrosine kinase that is very similar to the IR in structural and 
functional homology. In fact, in cells that express both receptors, hybrid receptors appear to 
fonn readily, yet the biological consequence of these hybrids is not clear (207). The receptor 
is a tetramer consisting of 2 extracellular a-chains and 2 intracellular {J-chains. An 
intracellular tyrosine kinase domain is found in the the {J-chain which is believed to be 
essential for most of the receptors' biological effects (208). In response to IGF-l, IGF-IR 
activation mediates tumor cell proliferation, motility, and protection from apoptosis. Binding 
of IGF -1 or insu lin, at very high, unphysiological concentrations, induces the activation of 
PTK domain of IGF-IR{J subunit, activating the autophosphorylation of the receptor 
(reviewed in (207»). Phosphorylation of adaptor/docking proteins, such as insu lin receptor 
substrate (IRS-l or IRS-2), Shc and Grb2 then takes place (153;209). IRS-l, as mentioned 
earlier, contains multiple tyrosine phosphorylation sites that recognize and bind SH2-
containing signalling molecules, such as Grb2, Nck, the p85 subunit of PI3-K and the SHP2. 
Binding of Grb2/Sos to tyrosine-phosphorylated IRS-l activates Ras, which then stimulates 
the Raf-lIMAPK cascade (210). The activated IGF-IR also triggers PI3K, and its 
downstream targets, PKB/Akt and p70s6k (211;212). 
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1.6 - Anti-Diabetic Effects of Zinc 
1.6.1 - Effect on Glucose Transport 
The stimulatory effect of Zn on glucose transport has been observed in rat adipocytes 
(213;214), as well as in 3T3-Ll fibroblasts and 3T3-L1adipocytes (139). In most of these 
studies, high Zn concentrations were required to enhance glucose transport. For example, 
May and Contoreggi used up to 1000 ~M Zn (in the form of zinc chloride) to stimulate 
glucose transport (213). Ezaki later confirmed these experiments, using 1 000 ~M Zn to 
stimulate glucose transport in isolated rat adipocytes by a post receptor mechanism, which 
was 67% the value achieved with 1 nM insulin (214). Further investigations into the 
functioning of the molecular mechanisms of the anti-diabetic effects of Zn showed that Zn 
activated glucose transport in adipocytes and 3T3-L1 fibroblasts through activation of PI3K 
and PKB/ Akt (139), and in contrast to earlier studies, it was shown that 20 to 50 J.lM was 
sufficient to significantly increase glucose transport in 3T3-L1 adipocytes. Considering that 
normal Zn serum concentration range at approximately 15 ~M, concentrations varying from 
20 to 50 J.lM may be sufficient to evoke a physiologically-relevant increase in glucose 
transport (139). Noteworthy is the fact that in the study, Zn had a greater effect on glucose 
transport in 3T3-Ll adipocytes thank 3T3-L1 fibroblasts. This is explained by the fact that 
3T3-L1 adipocytes predominantly express insulin-sensitive glucose transporter protein type 4 
(GLUT4), and 3T3-Ll fibroblasts express insulin-insensitive GLUT1, showing that Zn acts 
here as an insulin-mimetic, since insulin-stimulated glucose transport is mediated by GLUT-4 
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(215;216). Ilouz et al. also showed that physiological concentrations of Zn (10 !lM), in 
the fonn -of ZnClz, stimulated glucose uptake in GLUT4 expressing isolated mouse 
adipocytes, to a much greater extent than in C6 rat glioma cells and GP8 rat brain endothelial 
cells, which both express GLUT1, and not GLUT4 (217). They go on to show that 
physiological concentrations of Zn inhibited glycogen synthase kinase 3~ (GSK-3~), and 
suggest that inhibition ofGSK-3~ by phosphorylation is essential for glucose uptake (217). 
1.6.2 - Effect on Glycogen Metabolism and Gluconeogenesis 
Another physiological response modulated by Zn is its action on glycogen synthesis. 
As early as 1985, it was shown that rat livers exposed to Zn salts for 30 days contained twice 
as much glycogen as those of control rats (218). Not only was there more glycogen, but the 
st orage of glycogen in the liver of the rats was also accelerated by feeding them Zn, in the 
fonn of zinc acetate (218). More recent studies have shown that Zn, in the fonn of ZnClz, 
phosphorylates GSK-3~ at physiological concentrations (15 !lM) in HEK-293 cells (217). 
GSK-3~ and Forkhead box protein 01 (FOX01) were also shown to be phosphorylated by 
ZnS04 in HepG2 cells. Phosphorylation of GSK-3~ inactivates it, causing increased 
glycogen synthesis by upregulating glycogen synthase (182). Phosphorylation of FOX01, a 
transcription factor largely involved in glucose metabolism, causes it to become inactive. 
FOX01 is therefore excluded from the nucleus causing an inhibition of hepatic glucose 
production, through the inhibition of gene expression of gluconeogenic enzymes (179). An 
inhibitory effect of Zn on gluconeogenesis in rat renal cortex slices, as weIl as rat liver 
parenchymal cells, has also been demonstrated (219;220). It may be suggested that Zn -
induced activation of PI3K1PKB signalling through GSK-3 and FOXO 1 contributes to 
enhanced glycogen synthesis, as well as decreased gluconeogenesis. 
1.6.3 - Effect on Lipogenesis and Lipolysis 
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In addition to their action on glucose metabolism, Zn has been reported to alter lipid 
metabolism both in vivo and in vitro. As mentioned earlier, Coulston and Dandona showed 
that Zn, in the form of zinc chloride (ZnCh) can mimic insu lin in its ability to stimulate 
lipogenesis in rat adipocytes (100). Later studies by May and Contoreggi showed that Zn was 
able to inhibit lypolysis in isolated rat adipocytes stimulated with the p-adrenergic agent 
ritodrine (213), albeit at a high concentration (500j..tM). This effect was thought to be due to 
Zn-induced H20 2 generation, since exogenous catalase reversed the inhibited lypolysis (213), 
and since H20 2 had already been shown to mimic a variety of insulins' actions, including 
lipogenesis and inhibition of lipolysis (221). In 1992 though, Shisheva et al. showed that 
ZnCh increased the uptake of glucose to lipids in rat adipocytes, with a maximum stimulation 
of lipogenesis 55-80% of maximum insu lin response (222). They also showed that this event 
was not due to H20 2 production by ZnCh as catalase treatment did not inhibit ZnCh induced 
glucose oxidation and its incorporation into lipids (222). More recently, insulin mimicking 
suppression of lipolytic activity was exhibited when both ZnS04 and Zn(Mal)2 (116), as well 
as Zn(alx)2 (121) showed a potent inhibition of free fatty acid release from epinephrine-
stimulated rat adipocytes. 
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1.6.4 - Goal of tbis Stndy 
As discussed above, Zn compounds have been found to have anti-diabetic, insu lin-
mimetic, and insulin-potentiating in a plethora of cellular studies, as well as in rodent models 
of type 1 and type Il diabetes mellitus, and in a limited number of hum an studies. These 
compounds have been shown to enhance and/or mimic insulin action, which inc1udes 
increasing glucose transport, glycogen synthesis and lipogenesis as well as inhibition of 
gluconeogensis and lipolysis. In in vitro systems, the molecular mechanism of Zn compounds 
correlates with the activation of different components of the insulin signalling pathway, such 
as PI3-K and ERKl/2. However, the precise mechanism by which Zn compounds enhance or 
mimic insulin-like effects is still poorly characterized. There are conflicting data and the 
precise upstream elements responsible for mediating the Zn-induced activation of ERKl/2 
and PKB signalling have not yet been identified. AIso, a precise role of IR in mediating the 
insulin-like effects of Zn in vivo and in vitro systems remains to be established. 
Therefore, the studies presented in this work were undertaken to elucidate a possible 
role for IR, IGF-IR and EGFR receptor tyrosine kinases on PKB and ERKl/2 
phosphorylation by Zn in CHO cells. These studies have used standard protocols of cel1ular 
and molecular biology such as cell culture, immunoprecipitation and western blotting, and 
have also used cells that express wild type or tyrosine kinase deficient fOnTIS of IR and IGF-
IR. 
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Chapter 2 
Extracellular Zn2+-induced activation of ERK1I2 and PKB phosphorylation requires 
insulin like growth factor-l receptor (IGF-IR) and is independent of insulin receptor 
(IR) protein tyrosine kinase (PTK). 
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ABBREVIATIONS 
CHO, Chinese hamster ovary; CHO-BIR, CHO cells overexpressed with human insulin 
receptor; CHO-l 018, CHO cells over-expressing a mutant human insulin-receptor in which 
Lysine 1018 has been replaced by alanine causing a complete 10ss of the PTK activity of 
insu1in receptor; ERKl/2, extracellular signal-regulated kinase 1 and 2; EGF, epidermal 
growth factor; EGFR, EGF receptor; IGF-l, insulin-like growth factor-l; IGF-IR, IGF-l 
receptor; IR, insulin receptor; IRS-1, insulin receptor substrate-l; MAPK, mitogen-
activated protein kinase; MCF-7, human breast carcinoma MCF-7 cells; PI3-K, 
phosphatidy1inositol 3-kinase; PKB, protein kinase B; PMSF, phenylmethylsulphonyl 
fluoride; PVDF, polyvinilidene difluoride. 
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Abstract 
Recent studies have demonstrated that Zn2+ exerts insulin-mimetic and anti-diabetic effects 
in rodent models of insulin-resistance. Zn2+ was also shown to activate ERK1I2 and 
PI3K1PKB, two key components of the insulin signaling pathway. Zn2+ -induced signaling 
was associated with an increase in the tyrosine-phosphorylation of insulin receptor (IR), as 
weIl as phosphorylation of insulin-like growth factor-l receptor (IGF-IR) and epidermal 
growth factor receptor (EGFR), however, the specific contribution of each ofthese receptor 
prote in tyrosine kinases (R-PTKs) in Zn2+-induced responses remains to be established. 
Therefore, in the present studies, by using a series of pharmacological inhibitors and cells 
that overexpress normal and mutant/inactive forms of IR and IGF-IR, we have investigated 
the role of R-PTKs in Zn2+ -induced ERK1I2 and PKB phosphorylation. Zn2+ stimulated 
ERK1I2 and PKB phosphorylation in a dose and time-dependent manner in Chinese 
hamster ovary cells overexpressing IR (CHO-HIR). Pretre atm ent with AGI024, an 
inhibitor for IR- and IGF-IR-PTK, blocked Zn2+-induced ERK1I2 and PKB 
phosphorylation, but AG1478, an inhibitor for EGFR was without effect. In CHO cells 
overexpressing tyrosine kinase deficient IR (CHO-IOI8), Zn2+ was still able to induce the 
phosphorylation of these two signaling molecules, whereas insulin effect was significantly 
attenuated. Furthermore, both Zn2+ and IGF-I failed to stimulate ERK1I2 and PKB 
phosphorylation in IGF-IR KO cells. In addition, Zn2+ had no effect on the tyrosine 
phosphorylation of IR-~-subunit and IRS-I in CHO-HIR cells. Taken together, these data 
suggest that Zn2+ -induced ERK1I2 and PKB phosphorylation is independent of IR- or 
EGFR-PTK, yet nonetheless requires IGF-IR-PTK. 
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Zinc (Zn2+), one of the most abundant trace metals, is fundamental for structural and 
regulatory cellular functions. It plays critical roles in insulin biosynthesis, storage and 
insulin secretion from pancreatic ~ cells (1-4). Zn2+ has also been shown to exert insulin-
mimetic (5-9) and anti-diabetic (10-14) effects in various rodent models of insu lin 
resistance, and has also been shown to activate lipogenesis and glucose transport in 
adipocytes (9;15;16). Zn2+-deficient rats have abnormal glucose tolerance, which cou Id be 
reversed by Zn2+ repletion (5). Additionally, dietary Zn2+ supplementation has been 
reported to attenuate hyperglycemia in leptin receptor deficient db/db mice (10). 
Furthermore, type 2 diabetic subjects have been reported to exhibit lower serum levels of 
Zn2+ as compared to healthy individuals (17; 18), indicating that Zn2+ deficiency might be 
linked with insulin resistance. 
In a plethora of studies, Zn2+ was demonstrated to activate several key components of the 
insulin signaling pathways, such as mitogen-activated protein kinases (MAPKs), 
extracellular-regulated protein kinase 1 and 2 (ERKl/2) (19-23), phosphatidylinositol 3-
kinase (PI3K) (22;24), protein kinase B (PKB/Akt) (8;21;22;24-27), mammalian target of 
rapamycin (mTOR), as weIl as p70S6K in several cell types (24;28). Early studies did not 
detect any increase in insulin receptor protein tyrosine kinase (IR-PTK) in rat adipocytes 
stimulated with Zn2+ (15). AIso, certain in vitro studies suggested an inhibitory effect by 
Zn2+ on insulin-induced IR autophosphorylation (29). In contrast, later studies have shown 
an increase in the Zn2+ -induced tyrosine phosphorylation ofIR-PTK(26;30-32). However, 
divergent effects of Zn2+ on upstream tyrosine kinases responsible for activating these 
signaling pathways have been suggested. For example, Zn2+ treatment of 3T3-Ll 
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fibroblasts and adipocytes showed an increased phosphorylation of the p-subunit of 
insulin receptor (IR) (26), whereas it had no effect on IR-PTK in rat adipocytes (J 5). 
Moreover, in vitro studies demonstrated that Zn2+ exerted an inhibitory effect on insulin-
induced autophosphorylation of IR (29). Additionally, Zn2+ was found to increase tyrosine 
phosphorylation of insulin-like growth factor type l receptor (IGF -1 R) in C6 glioma cells 
(33), and an important role of epidennal growth factor receptor (EGFR) in Zn2+-induced 
signal transduction has also been suggested in human epidennal A431 cells (34;35). Thus, 
the precise upstream elements responsible for provoking the Zn2+-induced activation of 
ERK1I2 aild PKB signaling remain to be elucidated. Furthennore, in view of the emerging 
insulin-like effects mediating the in vivo and in vitro systems, a potential role of IR in this 
process remains to be established. Therefore, in the present studies, by using a series of 
phannacological inhibitors of EGFR, IR and IGF-1R protein tyrosine kinases, as weIl as 
cells that overexpress nonnal and mutant/inactive fonn of IR and IGF -IR, we explored the 
molecular mechanism of extracellular Zn2+-induced phosphorylation ofERK1I2 and PKB. 
Material and Methods 
Antibodies and reagents: 
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Cell culture reagents were procured from Invitrogen Corp. (Grand Island, NY). Monoclonal 
phospho-specific ERK1I2 antibody and polyclonal ERK1I2 antibody; horseradish 
peroxidase-conjugated goat anti-mouse immunoglobulin were from Santa Cruz 
Biotechnology (Santa Cruz, CA). The phospho-Ser473-specific-PKB antibody, the PKB 
antibody and anti-rabbit antibody were procured from Cell ~ignaling (Beverly, MA). PTKs 
inhibitors, AGl024 and AG1478; and PI3K inhibitor, Wortamannin, were procured from 
Calbiochem (San Diego, CA). Insulin was purchased from Eli-Lily Co. (Indianapolis, IN). 
ZnS04 was obtained from Fischer Chemical (Pittsburg, P A). The enhanced 
chemiluminescence (ECL) detection system kit was from Amersham Pharmacia Biotech 
(Baie d'Urfé, Quebec, Canada). 
Cells and Cell culture: Parental Chinese hamster ovary (CHO) cells, CHO cells over-
expressing a normal human insulin receptor (HIR), CHO-HIR cells and CHO cells over-
expressing a mutant human insulin-receptor in which Lysine 1018 has been replaced by 
Alanine, causing a complete loss of the PTK activity of insu lin receptor (CHO-1018), were 
a kind gift from Dr. Morris F. White (Joslin Diabetes Center, Boston, MA, USA) (36). 
CHO-HIR and CHO-1018 cells were maintained on F-12 medium (Invitrogen, Burlington, 
ON, Canada) with 10% fetal bovine serum (FBS). 
MCF-7 breast cancer cells, MCF-7 wild type (MCF-7 WT) and MCF-7 stably transfected 
with an antÎsense IGF-IR cDNA (MCF-7 SX13) cells were a gift from D. LeRoith (NIH, 
Bethesda, Maryland) (37). MCF-7 normal cells were maintained on DMEM high glucose 
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medium with 10% FBS, while MCF-7 SX13 cells were grown on DMEM high 
glucose medium with G418 0.5g/L and 10% FBS (37). All cells were grown to 80% 
confluence in 60 mm plates and incubated in serum-free corresponding medium containing 
for 20 h and refresh with serum free corresponding medium 1h prior to the experiment. 
Immunoblotting : Cells incubated in the absence or presence of stimulating agents were 
washed twice with ice-cold PBS and lysed in 200 ~tl ofbuffer A (25 mM Tris-HCl, pH 7.5, 
25 mM NaCI, 1 mM Na orthovanadate, 10 mM Na fluoride, 10 mM Na pyrophosphate, 2 
mM benzamidine, 2 mM ethylenebis (oxyethylenenitrolo)-tetraacetic acid (EGTA), 2mM 
ethylenediamine-tetraacetic acid (EDT A), 1 mM phenylmethylsulphonyl fluoride (PMSF), 
10 f!g/ml aprotinin, 1 % Triton X -100 and 0.1 % sodium dodecyl sulfate (SDS), 0.5 ~lg/ml 
leupeptin on ice. The cells were scraped, collected and centrifuged at 12,000 g for 10 min. 
Protein concentrations were detennined by using Bradford assay. Equal amounts of protein 
were subjected to 10% SDS-P AGE, transferred to polyvinilidene difluoride (PVDF) 
membranes and incubated with monoclonal phospho-specific-ERK1/2 antibody (l :4000), 
with polyclonal phospho-Ser473 -specific-PKB antibody (1 :2000), detected by a horseradish 
peroxidase conjugated second antibody (1 :4000), and visualized with an ECL detection kit, 
as described earlier (38). The same blots were subsequently reprobed with ant-ERk1l2 or 
anti-PKB antibodies to detect the total amount ofthese proteins. 
Immunoprecipitation: Cleared ce 11 lysates after stimulation (as prepared for 
immunoblotting) were incubated either with the insulin receptor (IR) or insulin receptor 
substrate-1 (IRS-1) antibodies at 4°C ovemight. The antigen-antibody complexes were 
immunoprecipitated with protein A sepharose beads for 2h at 4°C. The immunoprecipitated 
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protein was then washed once with PBS IX containing inhibitors (1 mM 
phenylmethylsulphonyl fluoride (PMSF), 10 Ilg/ml aprotinin, 0.5 ~g/ml leupeptin and 1 
mM Na orthovanadate) and twice with cold lysate buffer, before solublization in Laemmli's 
sample buffer. 
Data analysis: Results from immunoblots were quantified by densitometric analysis of 
bands using NIH-image J, as weIl as the Syngene GeneTools software programs. Values 
presented here are means ± S.D. of at least three independent experiments. 
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Results 
Characterization of Zn2+ -induced ERIO!2 and PKB phosphorylation 
As shown in Fig 1, treatment of CHO-HIR cells with Zn2+ caused a dose-dependent 
(Fig. lA) and time-dependent (Fig. lB) increase in the phosphorylation of ERKl/2 and 
PKB. Increased phosphorylation of both ERK1/2 and PKB peaked at around 100 ~M of 
Zn2+. A time course analysis using 50 ~M Zn2+ revealed that Zn2+ treatment resulted in a 
time-dependent increase in the phosphorylation of both ERKl/2 and PKB in CHO-HIR 
cells. The phosphorylation was rapid and could be detected as early at 2 min of the 
treatment and showed a peak at 5 minutes in case of ERKl/2 and 15 min in case of PKB 
phosphorylation. These effects were sustained up to 60 minute time points. 
Effect of Zn2+-induced ERlO!2 and PKB phosphorylation is blocked by AGI024 
Zn2+ has been shown to increase the tyrosine phosphorylation of EGFR (34;35;39), IGF-
IR and IR (26;30-32), implying a role of these R-PTKs in Zn2+-induced signaling events, 
therefore, we examined a role of these R-PTKs in Zn2+ -induced ERKl/2 and PKB 
phosphorylation in CHO-HIR cells. For these experiments, we used AG1478, an inhibitor 
of EGFR-PTK (40) and AGl024, an inhibitor for IR-PTK and IGF-IR-PTK (41;42). As 
shown in Fig.2A, pretreatment of CHO-HIR cells with AG 1024 significantly blocked Zn2+_ 
induced ERKl/2 and PKB phosphorylation, whereas AG1478 exerted no significant 
inhibition (Fig.2B). 
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Effeet of Znz+on tyrosine phosphorylation ofIR-p subunit and IRS-l 
In addition to inhibiting IGF-1R-PTK, AG1024 also blocks the IR-PTK activity (41). 
Moreover, Zn2+ has been shown to enhance tyrosine phosphorylation of IR-p subunit in 
multiple cell types (26). Therefore, we directly assessed the effect of Zn2+ on tyrosine 
phosphorylation of IR-~ subunit. As shown in Fig.3A, Zn2+ treatment failed to enhance the 
tyrosine phosphorylation of IR-p subunit, while as expected, insu lin treatment resulted in a 
robust increase in IR-P subunit tyrosine phosphorylation. Since IRS-l phosphorylation is 
critical to propagate insulin/IGF-I-Înduced signaling, we next investigated if stimulation of 
PKB in response to Zn2+ was associated with IRS-l tyrosine phosphorylation. As shown in 
Fig.3B, similar to its effect on IR-P subunit phosphorylation, Zn2+ had no effect on IRS-l 
phosphorylation, whereas Însulin and IGF-l, when used as a positive control, had a 
stimulatory effect. 
Effeet of Zn2+ on ERKl/2 and PKB phosphorylation in IR-PTK deficient CHO-I018 
eells 
To further analyze the involvement ofIR-PTK in Zn2+-induced responses, we utilized CHO 
cells overexpressing a mutant form ofhuman IR, where the lysine 1018 in the ATP-binding 
domain was mutated to alanine. This mutant form is unable to bind ATP and lacks the 
phospho-transferase activity of IR-PTK (43). As shown in FigA, both Zn2+ and insulin 
enhanced the ERKl/2 and PKB phosphorylation in CHO cells overexpressing wild type IR 
(active IR) CHO-HIR. However, in CHO-lOI8, the insulin-induced ERKl/2 and PKB 
phosphorylation was significantly attenuated, whereas Zn2+-induced effect was unaffected. 
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Zn2+-induced ERKl/2 and PKB phosphorylation is mediated by IGF-IR 
The data presented above suggested that Zn2+ -induced effects on these signaling 
components were independent of IR-PTK activity. Since AG 1024, which is also an 
inhibitor of IGF-IR-PTK, blocked the stimulatory effect of Zn2+ on ERKll2 and PKB 
phosphorylation in CHO-HIR cells, we next examined the involvement of this PTK in 
mediating the response of Zn. For these experiments we used MCF-7 cells which express 
nonnal IGF-IR (IGF-IR, WT cells) and MCF-7 cells which are stably transfected with a 
mutant negative IGF-1R (IGF-1R KO SX-13 cells cells) (37). As depicted in Fig.6, 
ERK1/2 stimulation ofIGF-lR WT cells with either 10 nM IGF-l or 100 uM ofZn2+ for 5 
minutes resulted in a robust phosphoryation ofERKI/2 and PKB. However, in IGF-IR KO 
cells, both IGF -1 and Zn2+ -induced effects were significantly attenuated. 
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Discussion 
In the present studies, we have demonstrated that extracellular Zn2+ induces the 
phosphorylation of ERK 1/2 and PKB, two well established mediators of insu lin action. By 
using pharmacological and molecular approaches, we have also shown that Zn2+-induced 
responses on these signaling components primarily require activation of IGF-IR PTK. 
Earlier studies have also documented stimulatory effects of Zn2+ on MAPKinases, ERK1I2, 
p38mapk, c-JNK, p70s6k and PI3-K signaling in many different cell types (19-24;28). In 
addition, Zn2+ treatment was shown to induce transactivation of EGF-R in B 82L 
fibroblasts, as weIl as in A431 cells (35;39). Moreover, Zn2+-induced effects were linked 
with an increase in tyrosine phosphorylation of cellular proteins (31), and were suggested 
to be associated with the activation of IR (26;30;32). In contrast, other investigators have 
shown that Zn2+-induced actions were independent of IR (8;15;29) and EGF-R 
phosphorylation (35). 
Our studies are the first to investigate an involvement of EGF -RlIRIIGF -1 R in Zn2+_ 
induced ERK1I2 and PKB phosphorylation. Our data showing that AG1478, a high1y 
specific inhibitor ofEGF-R-PTK, failed to attenuate Zn2+-induced increase in ERK1I2 and 
PKB phosphorylation suggested that these events are independent of EGF-R PTK. In 
contrast to our CUITent study, by using PP-153035, another inhibitor ofEGF-R-PTK, a role 
ofEGF-R in Zn2+-induced ERK1I2 phosphorylation in A431 cells has been suggested (35). 
Existance of an EGF-R-independent mechanism for Zn2+-induced effects has also been 
suggested in studies demonstrating that PP2, a Src-PTK inhibitor, despite blocking Zn2+_ 
induced EGF-R tyrosine phosphorylation had no effect on Zn2+-induced ERK1/2 
phosphorylation (35). Thus, it may be possible that both EGFR-PTK -dependent and -
independent pathways contribute to Zn2+ -induced signaling. 
62 
Zn2+ has been suggested to exert various insulin-Iike effects (5-9). Insulin signaling is 
triggered wh en insulin binds to the a-subunit of the insulin receptor (IR) on the cell 
membrane resulting in conformational changes that activate intrinsic protein tyrosine kinase 
(PTK) activity of the ,B-subunit by its autophosphorylation in multiple tyrosine residues 
(44-46). In line with this, Zn2+ was shown to increase tyrosine phosphorylation of insu lin 
receptor l3-subunit in 3T3-Ll fibroblasts, as weIl as adipocytes (26). However, under these 
conditions, Zn2+ failed to enhance IRS-l or IRS-2 tyrosine phosphorylation in these cens 
(26). Contrary to these observations, Zn2+ did not increase tyrosine phosphorylation of IR in 
rat adipocytes (15) suggesting that Zn2+ exerts insulin-like effects through an IR-
independent pathway. Further studies have supported the later view and suggested that Zn2+ 
mimi cs several actions of insu lin, both in vitro and in vivo by a mechanism unrelated to 
insulin signaling (8). The inability ofZn2+ to increase tyrosine phosphorylation ofIR-b and 
IRS-l in our studies support these later studies, and suggests that Zn2+ -induced effects are 
not associated with IR-PTK functions. Our results showing that among various 
phannacological inhibitors tested, only AGI024, which is an inhibitor of IR/IGF-IR-PTK, 
attenuated Zn2+ -induced responses pointed towards an intennediary role of IR/IGF-IR in 
this process. However, the fact that phosphorylation of ERK1I2 and PKB in response to 
Zn2+ was identical in CHO-HIR and IR-PTK-deficient CHO-IOIS cens clearly 
demonstrated that Zn2+ signaIs in an IR-PTK-independent fashion. Since AGI024 also 
targets IGF-IR-PTK, we further tested the involvement ofIGF-lR receptor in Zn2+ -induced 
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ERK1I2 and PKB phosphorylation. We found that Zn2+, as well as IGF-l induced 
ERK1I2 and PKB phosphorylation, was almost completely suppressed in IGF-IR KO cells, 
but not in the cells with normal IGF-IR expression. Normally, IGF-l-induced signaling 
requires IRS-l to propagate downstream signaling events to activate MAPK and PI3K1PKB 
pathways; exceptionally in this study, we observed that Zn2+ was unable to induce IRS-l 
phosphorylation in CHO-HIR cells. Similar findings have also been reported by others 
(26;33), and additional work in transgenic IRS-l knockout mice has suggested the 
existence ofIRS-l-independent signaling pathways (47;48). It has also been suggested that 
the p85 subunit ofPI-3Kinase directly interacts with IR (49) and that a direct interaction of 
p85, Syp and GAP, and the IGF-IR is possible (50). Thus Zn2+-induced responses of 
ERK1I2 and PKB phosphorylation might be mediated through direct interaction of P85/PI-
3Kinase with IGF-IR, as suggested earlier (50). 
In summary, our studies have provided first experimental evidence for a role of IGF-IR-
PTK in Zn2+-induced activation ofERK1I2 and PKB signaling pathway, independent to the 
action of EGF-R and IR-PTK. We have also demonstrated that IRlIRS-l tyrosine 
phosphorylation may not be necessary to transduce Zn2+ -induced responses in Zn2+ -induced 
responses. These data provide novel insight into the cellular mechanism of Zn2+ action. 
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Figure Legends 
Figure 1. Zn2+-induced dose response and time course ofERK1I2 and PKB 
phosphorylation: Serum-starved quiescent CHO-HIR cells were treated with or with out 
Zn2+ at indicated concentrations for 5 min, and at 50 ).lM Zn2+ at the indicated time points 
(Fig. lB). Cell lysates were prepared and equal amounts of protein was separated on 10% 
SDS-PAGE. ERK1I2 and PKB phosphorylation was detected by immunoblot analysis with 
phospho-specific ERK1I2 and PKB antibodies. Blots were also analyzed for total ERK1I2 
and PKB. The blots represent at least three independent experiments. 
Figure 2. Effect ofEGF-R, IR and IGF-tR tyrosine kinase inhibitors on Zn2+-induced 
ERK1I2 and PKB phosphoryJation: Serum-starved quiescent CHO-HIR cells were 
treated with or with out insulin (100 nM), EGF (100 nM) or Zn2+ (100 ).lM) in presence or 
absence of 10 ).lM of AGl024 (IR/IGF-lR PTK inhibitor) or AG1478 (EGF-R PTK 
inhibitor) pre-incubation for 30 minutes, as indicated. Cell lysates were prepared and equal 
amounts ofprotein was separated on 10% SDS-PAGE. ERKll2 and PKB phosphorylation 
was detected by immunoblot analysis with phospho-specific ERK1I2 and PKB antibodies. 
Blots were also analyzed for total ERKl/2 and PKB. The blots represent at least three 
independent experiments. 
Figure 3. Zn2+ dose not stimulate IR-P or IRS-l in CHO-HIR cells: Serum-starved 
quiescent CHO-HIR cells were treated with or with out insulin (100 nM), IGF-l(10ng/ml) 
or Zn2+ (1 00 ~M) for 5 minutes, (Fig.3A,B) for 5 minutes. For IR- phosphorylation cleared 
cell lysates were immunoprecipitated with IR and immunoblotted with p-Tyr. To see the 
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status of IRS-l phosphorylation, c1eared cell lysates were immunoprecipitated with 
IRS-l and immunoblotted with p-Tyr. Results shown here represent at least three 
independent experiments. 
Figure 4. Zn2+ induces ERK1I2 and PKB phosphorylation in IR-deficient CHO-IOI8 
cells. Serum-starved quiescent CHO-HIR and CHû-IOI8 cells were treated with or with 
out insu lin or Zn2+ for various concentrations as indicated for 5 minutes. Celllysates were 
prepared and equal amounts of protein was separated on 10% SDS-PAGE. ERK1I2 and 
PKB phosphorylation was detected by immunoblot analysis with phospho-specific ERK1I2 
and PKB antibodies. Blots were also analyzed for total ERK1I2 and PKB. A. Insulin-
stimulated ERK1I2 and PKB phosphorylation in CHO-HIR and CHO-1018 cells, B. Zn2+-
stimulated ERK1I2 and PKB phosphorylation in CHO-HIR and CHO-1018 cells. Values 
are the means ± SE of at least three independent experiments. 
Figure 5. Zn2+-induced ERK1I2 and PKB phosphorylation is attenuated in IGF-IR-
defecient SX-13 cell: Serum-starved quiescent MCF-7 and MCF-7 SX13 cells were treated 
with or with out IGF-l (10 nM) or Zn2+ (100 flM) for 5 minutes. Cell lysates were 
prepared and equal amounts of protein was separated on 10% SDS-PAGE. ERK1I2 and 
PKB phosphorylation was detected by immunoblot analysis with phospho-specific ERK1I2 
and PKB antibodies. Blots were also analyzed for total ERK1I2 and PKB. Values are the 
means ± SE of at least three independent experiments. 
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Chapter 3 - General Discussion 
A potential role of Zn in insulin action was suggested as early as 1966, when it was 
found that Zn deficient animaIs were less sensitive to insulin (101). The demonstrations a 
decade later that Zn could stimulate lipogenesis in rat adipocytes further strengthened the 
insulin-mimetic role of Zn (100). Later studies examined the effect of Zn on glucose 
transport in rat adipocytes (213;214), 3T3-L1 fibroblasts and 3T3-Lladipocytes (139), and 
showed that treatment of these cells with ZnCh/ZnS04 induced glucose uptake by about 2 
fold. Since then, these findings were extended to include the effects of Zn treatment in 
animal models of type 1 and type 2 diabetes mellitus. These studies revealed that Zn 
treatment partially prevented hyperglycaemia and development of diabetes in STZ rat 
model of type 1 diabetes (103). Similarly, Zn supplementation attenuated fasting 
hyperglycaemia and hyperinsulinemia in ob/ob mouse model of type 2 diabetes mellitus 
(108). 
Multiple studies were aiso performed at the cellular level, showing that Zn can 
mimic insulin and activate several key elements of the insulin signal transduction pathway. 
For example, activation ofPI3K (129), as weIl as PKB/Akt, in multiple celI types, such as 
in airway epithelial cells, HT -29 colorectal cancer cells, 3t3-L1 fibroblasts and rat 
adipocytes (127;139;181;222;237) was shown. Similarly, Zn was found to activate 
ERK1I2 in HT-29 ceUs (125) and bronchial epithelial celIs (236). 
Zn treatment aiso enhanced IR phosphorylation in rat adipocytes, digestive gland 
cells, and 3T3-Ll fibroblasts (36;139;240;241), although earlier studies had not detected 
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any increase in IR-PTK or IR-phosphorylation in rat adipocytes stirnulated with Zn. 
In fact, sorne studies even suggested an inhibitory effect of Zn on insulin-induced IR 
autophosphorylation (239). A role ofIGF-1R and EGFR in Zn-induced ERK 112 and PKB 
signal initiation was a1so suggested in C6 gliorna cells (198) and hurnan epidermal A431 
cells (126;242), respective1y. 
In view of these conflicting data on the role of various receptor PTKs in initiating 
Zn-induced signalling events, the present studies were undertaken to investigate a role for 
receptor PTKs in Zn-induced ERK1I2 and PKB/Akt phosphorylation. For these 
experirnents, we have used AG1478, an inhibitor ofEGFR-PTK and AG1024, an inhibitor 
for IR-PTK and IGF-1R-PTK. Our data suggests that EGFR does not participate in either 
PKB or ERK1I2 activation by Zn in CHO-IR cells, since AG1478 had no inhibitory effect 
on PKB or ERK1I2 phosphorylation in response to Zn. Thus, our results are in conflict 
with earlier studies in A431 cells where a role of EGFR activation in Zn-induced ERK1I2 
and PKB activation was dernonstrated (126;242). However, our work is supported by the 
studies where PP2, a Src-PTK inhibitor, despite blocking Zn-induced EGFR tyrosine 
phosphorylation, failed to inhibit Zn-induced ERK1I2 phosphorylation (126), and suggests 
the existence of an EGFR-independent rnechanisrn of Zn-induced signalling. 
As for AG1024, it significantly blocked Zn-induced ERK1I2 and PKB 
phosphorylation, irnplying that either IR or IGF -1 R plays a role in the signal transduction. 
To further probe the role of IRIIGF-1R in this process, we assessed the effect of Zn 
on tyrosine phosphorylation of IR-~ subunit. Zn2+ treatrnent failed to enhance the tyrosine 
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phosphorylation of IR-p subunit, while as expected, insu lin treatment resulted in an 
increase in IR-P subunit tyrosine phosphorylation. ûur results differ from earlier studies 
showing that Zn enhances tyrosine phosphorylation of IR-p subunit in multiple cell types 
(36;139;240;241). 
To further analyze the involvement of IR-PTK in Zn-induced responses, we utilized 
CHû cells overexpressing a mutant form of human IR, in which the lysine 1018 in the 
ATP-binding domain was mutated to alanine (249). Both Zn and insulin enhanced the 
ERK1I2 and PKB phosphorylation in CHû-IR cells. However, in CHû-1018 cells, insu lin-
induced ERK1I2 and PKB phosphorylation was significantly attenuated, whereas Zn-
induced effect was unaffected, providing further evidence that IR is not necessary for Zn-
induced ERK1I2 and PKB activation in CHû cells. 
Since AG 1024 also blocks IGR-IR, we examined the involvement of this PTK in 
mediating the response of Zn. For these experiments we used MCF-7 cells which express 
normal IGF-IR (IGF-IR, WT cells) and MCF-7 cells which are stably transfected with a 
mutant IGF-IR negative SX-13 cells (IGF-IR Kû cells). We found that stimulation of 
IGF-IR WT cells with Zn resulted in a robust phosphorylation of ERK1I2 and PKB. 
However, in IGF-IR Kû cells, both IGF-l and Zn-induced effects were completely 
attenuated, providing the first evidence for a role of IGF -1 R in Zn-induced ERK 1/2 and 
PKB activation, independent to EGFR activation and IR/IRS-l tyrosine phosphorylation. 
Taken together, we have demonstrated for the first time that IGF-IR is required for 
Zn-induced activation of ERK1I2 and PKB in CHû-IR cells, and that this activation is 
independent ofIR/lRS-l and EGFR-PTK activation, providing original insight into the 
cellular mechanism of Zn action. 
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Chapter 4 - Conclusion 
The results presented here demonstrate for the first time the requirement of the IGF-
IR in mediating Zn-induced phosphorylation of ERK1I2 and PKB/Akt in CHO-IR cells. 
We also show that the activation of ERK1I2 and PKB/ Akt by Zn occurs independently of 
the action of IR and IRS-I. These results were obtained by using AGI 024, a specific 
pharmacological inhibitor ofIRlIGF-IR-PTK, as well as mutant/inactive IR overexpressing 
cells, and IGF-IR KO cells. In contrast to other studies, our studies show that AGI478, a 
highly specific inhibitor of EGFR-PTK, failed to attenuate Zn-induced increase in ERK1I2 
and PKB phosphorylation, suggesting that these events are independent ofEGFR-PTK. 
The precise mechanism by which Zn activates IGF-IR in CHO cells, however, 
remains unc1ear. Nonetheless, since Zn is known to have a potent PTPase inhibitory effect, 
it may be suggested that Zn treatment can shift the equilibrium of the phosphorylation-
dephosphorylation cycle, resulting in a net increase of the tyrosine phosphorylation ofIGF-
IR and/or other proteins, which may trigger the IGF-IR-PTK signalling cascade. Even 
though our work provides novel insight into the cellular mechanism of Zn action, further 
studies are required to elucidate the precise mechanism through which IGF-IR is activated, 
and transmits its signal to induce phosphorylation of ERKI/2 and PKB/Akt pathways, 
which, in the long run, may help to develop new therapies to manage / treat diabetes and 
associated complications. 
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Figure 8: A model summarizing the mechanisms of Zn-induced responses in IGF-IR 
signalling. 
lOF-IR seems to be required for Zn-induced phosphorylation of ERKII2 and PKB, since 
these events were blocked by AO 1024. The mechanism by which Zn stimulates ERKII2 
and PKB phosphorylation is still unknown, but the ability of Zn to inhibit PTPases, as weIl 
as to stimulate lOF -1 Rand PI3-K might contribute to this effect. 
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